The Boston biotech is also looking into "strategic options" after its only clinical-stage drug showed disappointing Phase 1 ...
Elevation Oncology (NASDAQ:ELEV) lost ~37% in the premarket on Thursday after the company announced its plans to discontinue R&D work related to its antibody-drug conjugate (ADC) EO-3021 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback